Lantheus to receive supply of LEU-derived Mo-99 from ANSTO

12/20/2009 | AuntMinnie.com (free registration)

The Australian Nuclear Science and Technology Organisation has agreed to provide U.S. firm Lantheus Medical Imaging with molybdenum-99 derived from low-enriched uranium for use in its TechneLite generator line being marketed in U.S. and Canada. Lantheus and ANSTO are working with U.S. and Canadian regulators to obtain the necessary approvals for the distribution of LEU-derived Mo-99 in U.S. and Canadian markets.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA